Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer

Cancer Commun (Lond). 2019 Nov 21;39(1):78. doi: 10.1186/s40880-019-0423-3.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Nivolumab / therapeutic use*
  • Progression-Free Survival
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab